However, the only RCT that has evaluated the efficacy of pembrolizumab in patients with previously treated PD-L1-positive NSCLC and advanced NSCLC reported that adverse events of special interest based on immune etiology occurred in 69 of 339 patients (20%) in the 2 mg/kg group and 64 of 343 patients (19%) in the 10 mg/kg group [21]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.